Vacunas antiinfecciosas de mucosas en la profilaxis de infecciones recurrentes: más allá de las vacunas convencionales

Sánchez-Ramón, Silvia; Manzanares, Mario Javier Donate; Candelas, Gloria

doi:10.1016/j.reuma.2018.10.012

Cited by 5 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Perlingual polybacterial vaccines have already been used to prevent repeated infections in immunocompetent patients [ 6 ], and subsequently used in immunocompromised patients [ 7 ]. In this setting, perlingual polybacterial vaccines have been shown to enhance trained immunity and also adaptive responses against specific antigens contained in the bacterial combination, for which they are conceptualized among the so-called trained-immunity-based vaccines (TIbV) [ 8 , 9 , 10 , 11 , 12 , 13 ]. TIbV represent a promising strategy in the prevention of recurrent bacterial and viral infections, reducing the use of antibiotics and the concomitant occurrence of resistances.…”

Section: Introductionmentioning

confidence: 99%

Long-Term Benefit of Perlingual Polybacterial Vaccines in Patients with Systemic Autoimmune Diseases and Active Immunosuppression

et al. 2023

Self Cite

View full text Add to dashboard Cite

Introduction: We have previously shown that trained-immunity-based vaccines, namely TIbV, significantly reduce the rate of recurrent infections, both of the respiratory tract (RRTI) and urinary tract infections (RUTI) in SAD patients on disease-modifying drugs (DMARDs). Objective: We evaluated the frequency of RRTI and RUTI from 2018 to 2021 in those SAD patients that received TIbV until 2018. Secondarily, we evaluated the incidence and clinical course of COVID-19 in this cohort. Methods: A retrospective observational study was conducted in a cohort of SAD patients under active immunosuppression immunized with TIbV (MV130 for RRTI and MV140 for RUTI, respectively). Results: Forty-one SAD patients on active immunosuppression that were given TIbV up to 2018 were studied for RRTI and RUTI during the 2018–2021 period. Approximately half of the patients had no infections during 2018–2021 (51.2% no RUTI and 43.5% no RRTI at all). When we compared the 3-year period with the 1-year pre-TIbV, RRTI (1.61 ± 2.26 vs. 2.76 ± 2.57; p = 0.002) and RUTI (1.56 ± 2.12 vs. 2.69 ± 3.07; p = 0.010) episodes were still significantly lower. Six SAD patients (four RA; one SLE; one MCTD) with RNA-based vaccines were infected with SARS-CoV-2, with mild disease. Conclusions: Even though the beneficial protective effects against infections of TIbV progressively decreased, they remained low for up to 3 years, with significantly reduced infections compared to the year prior to vaccination, further supporting a long-term benefit of TIbV in this setting. Moreover, an absence of infections was observed in almost half of patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Long-Term Benefit of Perlingual Polybacterial Vaccines in Patients with Systemic Autoimmune Diseases and Active Immunosuppression

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Preparing for the Next Pandemic: Increased Expression of Interferon-Stimulated Genes After Local Administration of Nasalferon or HeberNasvac

Aguiar Santiago,

Marrero Miragaya,

Figueroa Oliva

et al. 2023

DNA and Cell Biology

View full text Add to dashboard Cite

Mucosal bacterial vaccines in clinical practice – a novel approach to an old problem?

Machado

Costa

et al. 2020

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

SUMMARY OBJECTIVES To evaluate the efficacy of mucosal bacterial vaccines (MBV) in reducing the number of exacerbations in patients with chronic respiratory disease. METHODS A prospective cohort study of patients followed at the Pneumology Unit of the University and Hospital Centre of Coimbra, with frequent infectious exacerbations (3 or more) despite the best therapeutic strategies employed. MBV was used as additional therapy. The number of exacerbations 1 year before therapy and 1 year after it were analyzed. RESULTS A sample of 11 individuals, 45.5% male, mean age 62.5 years. Eight patients had non-cystic fibrosis bronchiectasis, 2 COPD (1 on long-term oxygen therapy), and 1 patient with Mounier Kuhn’s syndrome. Three patients were on azithromycin, 1 on inhaled colistin, and 2 on inhaled tobramycin. Out of the 11 patients, one presented complication (fever), which led to a suspension of therapy (excluded from results). Of the 10 patients who completed treatment, 5 had bacterial colonization and were submitted to a custom vaccine. The remaining 6 completed the standard composition. The average of infectious exacerbations in the previous year was 4.3 (0.7 with hospitalization). In the year after therapy, the mean number was 1.5 (0.5 with hospitalization). CONCLUSION The results obtained in this study favor the use of bacterial immunostimulation to reduce the frequency of RRIs in patients with chronic respiratory disease.

show abstract

Vacunas antiinfecciosas de mucosas en la profilaxis de infecciones recurrentes: más allá de las vacunas convencionales

Cited by 5 publications

References 49 publications

Long-Term Benefit of Perlingual Polybacterial Vaccines in Patients with Systemic Autoimmune Diseases and Active Immunosuppression

Long-Term Benefit of Perlingual Polybacterial Vaccines in Patients with Systemic Autoimmune Diseases and Active Immunosuppression

Preparing for the Next Pandemic: Increased Expression of Interferon-Stimulated Genes After Local Administration of Nasalferon or HeberNasvac

Mucosal bacterial vaccines in clinical practice – a novel approach to an old problem?

Contact Info

Product

Resources

About